Sublingual immunotherapy for treating allergic conjunctivitis (Q24235657)

inferred from title

author

Giorgio Walter Canonica

4

object named as

Giorgio W Canonica

0 references

Stephen R Durham

5

object named as

Stephen Durham

0 references

Moises A Calderon

1

object named as

Moises A Calderon

0 references

author name string

Martin Penagos

2

0 references

Aziz Sheikh

Cochrane Database of Systematic Reviews

3

0 references

publication date

6 July 2011

0 references

published in

0 references

cites work

Efficacy of sublingual specific immunotherapy in Cupressaceae allergy using an extract of Cupressus arizonica. A double blind study

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

Sublingual-swallow immunotherapy with standardized 3-grass pollen extract: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

Efficacy and safety of specific immunotherapy with a high-dose sublingual grass pollen preparation: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

Sublingual immunotherapy: a double-blind, placebo-controlled trial with Parietaria judaica extract standardized in mass units in patients with rhinoconjunctivitis, asthma, or both.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

A prospective, randomized, double-blind, placebo-controlled multi-centre study on the efficacy and safety of sublingual immunotherapy (SLIT) in children with seasonal allergic rhinoconjunctivitis to grass pollen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

Sublingual immunotherapy with grass pollen is not effective in symptomatic youngsters in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

Randomized controlled trial of high-dose sublingual immunotherapy to treat seasonal allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

Sublingual immunotherapy in tree pollen allergy. Double-blind, placebo-controlled study with a biologically standardised extract of three pollens (alder, birch and hazel) administered by a rush schedule

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

Double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

Impact of sublingual immunotherapy on specific antibody levels in asthmatic children allergic to house dust mites

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

Clinical efficacy of sublingual-swallow immunotherapy: a double-blind, placebo-controlled trial of a standardized five-grass-pollen extract in rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

Grass allergen tablet immunotherapy relieves individual seasonal eye and nasal symptoms, including nasal blockage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

Implementation of pre-seasonal sublingual immunotherapy with a five-grass pollen tablet during optimal dosage assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

A randomized controlled trial of sublingual immunotherapy for Japanese cedar pollinosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

Effect of specific immunotherapy added to pharmacologic treatment and allergen avoidance in asthmatic patients allergic to house dust mite.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

Efficacy and safety of 5-grass pollen sublingual immunotherapy tablets in patients with different clinical profiles of allergic rhinoconjunctivitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

Sublingual tryptase and ECP in children treated with grass pollen sublingual immunotherapy (SLIT): safety and immunologic implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

Effects on inflammation parameters of a double-blind, placebo controlled one-year course of SLIT in children monosensitized to mites

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

Three-year follow-up of clinical and inflammation parameters in children monosensitized to mites undergoing sub-lingual immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

A randomized double-blind comparative study of sublingual immunotherapy for cedar pollinosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

Impact of sublingual immunotherapy on seasonal asthma and skin reactivity in children allergic to Parietaria pollen treated with inhaled fluticasone propionate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

A double-blind, placebo-controlled trial by the sublingual route of immunotherapy with a standardized grass pollen extract

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

Clinical data and inflammation parameters in patients with cypress allergy treated with sublingual swallow therapy and subcutaneous immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

'Well days' after sublingual immunotherapy with a high-dose 6-grass pollen preparation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

Allergen immunotherapy for asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

Fluticasone furoate nasal spray reduces the nasal-ocular reflex: a mechanism for the efficacy of topical steroids in controlling allergic eye symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

Operating characteristics of a rank correlation test for publication bias

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

Effects of adjuvant therapy with 0.1% olopatadine hydrochloride ophthalmic solution on quality of life in patients with allergic rhinitis using systemic or nasal therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

Current opinion of immunotherapy for ocular allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

Differential diagnoses of conjunctivitis for clinical allergist-immunologists

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

21 January 2018

Ocular allergy overview

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

Ocular symptom reduction in patients with seasonal allergic rhinitis treated with the intranasal corticosteroid mometasone furoate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

Allergic eye disease--a clinical challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

Sublingual immunotherapy: what have we learnt from the 'big trials'?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

Differentiating conjunctivitis of diverse origins

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

Immune mechanisms of allergen-specific sublingual immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

People and eyes: statistical approaches in ophthalmology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

Sublingual immunotherapy for allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

Mechanisms of sublingual immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

The epidemiology of ocular and nasal allergy in the United States, 1988-1994

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

Recent developments in meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

Evaluation of desloratadine on conjunctival allergen challenge-induced ocular symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

A double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized cat extract

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

7 January 2021

Tradition and innovation: finding the right balance

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

7 January 2021

Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

7 January 2021

Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

7 January 2021

Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

7 January 2021

Response to sublingual immunotherapy with grass pollen extract: monotherapy versus combination in a multiallergen extract

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

7 January 2021

Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

7 January 2021

Efficacy of sublingual immunotherapy with high-dose mite extracts in asthma: a multi-center, double-blind, randomized, and placebo-controlled study in Taiwan

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

7 January 2021

Double-blind, placebo-controlled evaluation of grass pollen specific immunotherapy with oral drops administered sublingually or supralingually

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

7 January 2021

Clinical and immunologic effects of a rush sublingual immunotherapy to Parietaria species: A double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

7 January 2021

Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

7 January 2021

Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

7 January 2021

[Sublingual immunotherapy with cat epithelial extract. Personal experience]

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

7 January 2021

Canadian trial of sublingual swallow immunotherapy for ragweed rhinoconjunctivitis

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

7 January 2021

Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite-sensitive patients with rhinitis and asthma--a placebo controlled study

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

7 January 2021

Sublingual-swallow immunotherapy (SLIT) with a standardized five-grass-pollen extract (drops and sublingual tablets) versus placebo in seasonal rhinitis

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

7 January 2021

House-dust-mite sublingual-swallow immunotherapy (SLIT) in perennial rhinitis: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

7 January 2021

Clinical and immunologic effects of long-term sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

7 January 2021

Preseasonal local allergoid immunotherapy to grass pollen in children: a double-blind, placebo-controlled, randomized trial

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

7 January 2021

Immunomodulation during sublingual therapy in allergic children

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

7 January 2021

House-dust mite sublingual-swallow immunotherapy in perennial conjunctivitis: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

7 January 2021

Low dose sublingual therapy in patients with allergic rhinitis due to house dust mite.

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

7 January 2021

Sublingual versus injective immunotherapy in grass pollen allergic patients: a double blind (double dummy) study

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

7 January 2021

Efficacy and safety of high-doses sublingual immunotherapy in ultra-rush scheme in children allergic to grass pollen

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

7 January 2021

Allergic rhinitis due to house dust mites: evaluation of the efficacy of specific sublingual immunotherapy

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

7 January 2021

Dose dependence of immunological response to sublingual immunotherapy

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

7 January 2021

Randomized double-blind controlled study with sublingual carbamylated allergoid immunotherapy in mild rhinitis due to mites

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

7 January 2021

Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

7 January 2021

Sublingual immunotherapy with a standardized cat dander extract: evaluation of efficacy in a double blind placebo controlled study

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

7 January 2021

A survey of the burden of allergic rhinitis in Europe

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

7 January 2021

Agreement of efficacy assessments for five-grass pollen sublingual tablet immunotherapy

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

7 January 2021

Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

7 January 2021

Double‐blind placebo‐controlled study of sublingual immunotherapy with house dust mite extract (D. pt.) in children

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

7 January 2021

Clinical and immunologic effects of sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

7 January 2021

Clinical efficacy and safety of preseasonal sublingual immunotherapy with grass pollen carbamylated allergoid in rhinitic patients. A double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

7 January 2021

Safety of various dosage regimens during induction of sublingual immunotherapy. A preliminary study

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

7 January 2021

A double-blind placebo-controlled evaluation of sublingual immunotherapy with a standardized ragweed extract in patients with seasonal rhinitis. Evidence for a dose-response relationship

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

7 January 2021

Safety and efficacy of Juniperus ashei sublingual-swallow ultra-rush pollen immunotherapy in cypress rhinoconjunctivitis. A double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

7 January 2021

A pilot study of feasibility of ultra-rush (20-25 minutes) sublingual-swallow immunotherapy in 679 patients (699 sessions) with allergic rhinitis and/or asthma

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

7 January 2021

Levocetirizine in persistent allergic rhinitis: continuous or on-demand use? A pilot study

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

7 January 2021

Fluticasone furoate nasal spray consistently and significantly improves both the nasal and ocular symptoms of seasonal allergic rhinitis: a review of the clinical data

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007685.PUB2

7 January 2021

10.1002/14651858.CD007685.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

21735416

1 reference

Consolidated OpenCitations Corpus – April 2017